SELAS PHARMACIE DES BUTTES CHAUMONT : revenue, balance sheet and financial ratios

SELAS PHARMACIE DES BUTTES CHAUMONT is a French company founded 15 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in PARIS (75019), this company of category PME shows in 2018 a revenue of 3.2 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELAS PHARMACIE DES BUTTES CHAUMONT (SIREN 527735724)
Indicator 2024 2023 2022 2018 2017 2016
Revenue N/C N/C N/C 3 245 914 € 3 091 962 € 3 000 253 €
Net income 121 971 € -13 600 € 243 876 € 160 729 € 157 625 € 97 458 €
EBITDA N/C N/C N/C 321 574 € 256 855 € 222 356 €
Net margin N/C N/C N/C 5.0% 5.1% 3.2%

Revenue and income statement

In 2024, SELAS PHARMACIE DES BUTTES CHAUMONT generates positive net income of 122 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 97 k€ -> 122 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

121 971 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 165%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 33%. The balance between equity and debt is satisfactory.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

164.537%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

33.181%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

29.6%

Solvency indicators evolution
SELAS PHARMACIE DES BUTTES CHAUMONT

Sector positioning

Debt ratio
164.54 2024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Average

In 2024, the debt ratio of SELAS PHARMACIE DES BUTTE... (164.54) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
33.18% 2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Average

In 2024, the financial autonomy of SELAS PHARMACIE DES BUTTE... (33.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 216.14. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

216.141

Liquidity indicators evolution
SELAS PHARMACIE DES BUTTES CHAUMONT

Sector positioning

Liquidity ratio
216.14 2024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Good

In 2024, the liquidity ratio of SELAS PHARMACIE DES BUTTE... (216.14) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SELAS PHARMACIE DES BUTTES CHAUMONT

Positioning of SELAS PHARMACIE DES BUTTES CHAUMONT in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 225 transactions of similar company sales in 2024, the value of SELAS PHARMACIE DES BUTTES CHAUMONT is estimated at 1 702 805 € (range 1 185 806€ - 2 547 494€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
225 transactions
1185k€ 1702k€ 2547k€
1 702 805 € Range: 1 185 806€ - 2 547 494€
NAF 5 année 2024

Valuation method used

Net Income Multiple
121 971 € × 14.0x = 1 702 805 €
Range: 1 185 807€ - 2 547 494€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELAS PHARMACIE DES BUTTES CHAUMONT with other companies in the same sector:

Frequently asked questions about SELAS PHARMACIE DES BUTTES CHAUMONT

What is the revenue of SELAS PHARMACIE DES BUTTES CHAUMONT ?

The revenue of SELAS PHARMACIE DES BUTTES CHAUMONT in 2018 is 3.2 M€.

Is SELAS PHARMACIE DES BUTTES CHAUMONT profitable?

Yes, SELAS PHARMACIE DES BUTTES CHAUMONT generated a net profit of 122 k€ in 2024.

Where is the headquarters of SELAS PHARMACIE DES BUTTES CHAUMONT ?

The headquarters of SELAS PHARMACIE DES BUTTES CHAUMONT is located in PARIS (75019), in the department Paris.

Where to find the tax return of SELAS PHARMACIE DES BUTTES CHAUMONT ?

The tax return of SELAS PHARMACIE DES BUTTES CHAUMONT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELAS PHARMACIE DES BUTTES CHAUMONT operate?

SELAS PHARMACIE DES BUTTES CHAUMONT operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.